

Amendment to the Specification:

◊◊ Please replace Table 2 on page 79 with the amended Table 2 on the following page:

Table 2:

Steps in Antibody optimisation	Fab	$k_{on} [s^{-1}M^{-1}] \times 10^5 \pm SD$	$k_{off} [s^{-1}] \times 10^{-3} \pm SD$	$K_D [nM] \pm SD$	L-CDR3	L-CDR1
Parental Fab	MS-GPC-8	0.99 ± 0.40	29.0 ± 8.40	346.1 ± 140.5 ^a 59)	QSYDMPQA (SEQ ID NO: <u>22</u>)	SGSSNIGSNYVS (SEQ ID NO: 12)
L-CDR3-optim.	-8-1	1.93	20.9	108 ^e		
L-CDR3-optim.	-8-6	0.96 ± 0.14	5.48 ± 0.73	58.6 ± 11.7 ^b		
L-CDR3-optim.	-8-9	1.85	16.6	90.1 ^e		
L-CDR3-optim.	-8-10	nd	7.0 ^e	nd		
L-CDR3-optim.	-8-17	1.0	5.48	54.7 ^e		
L-CDR3-optim.	-8-18	1.06	8.3	78.3 ^e		
L-CDR3-optim.	-8-27	nd	6.6 ^e	nd		
L-CDR3-optim.	-8-6	0.96 ± 0.14	5.48 ± 0.73	58.6 ± 11.7 ^b	QSYDYDHY (SEQ ID NO: 60)	SGSSNIGSNYVS (SEQ ID NO: 12)
L-CDR3+1-opt.	-8-6-2	1.23 ± 0.11	0.94 ± 0.07	7.61 ± 0.25 ^c	QSYDYDHY (SEQ ID NO: 60)	SGSESNIGSNYVH (SEQ ID NO: 13)
L-CDR3+1-opt.	-8-6-19	1.10 ± 0.08	0.96 ± 0.15	8.74 ± 1.33 ^c	QSYDYDHY (SEQ ID NO: 60)	SGSESNIGSNYVA (SEQ ID NO: 14)
L-CDR3+1-opt.	-8-6-27	1.80 ± 0.24	1.10 ± 0.15	6.30 ± 0.63 ^d	QSYDYDHY (SEQ ID NO: 60)	SGSDSNIGANYVT (SEQ ID NO: 15)
L-CDR3+1-opt.	-8-6-45	1.20 ± 0.07	1.03 ± 0.04	8.63 ± 0.61 ^c	QSYDYDHY (SEQ ID NO: 60)	SGSEPNIGSNYVF (SEQ ID NO: 16)
L-CDR3+1-opt.	-8-6-13	1.90 ± 0.26	0.55 ± 0.05	2.96 ± 0.46 ^c	QSYDYDHY (SEQ ID NO: 60)	SGSESNIGANYVT (SEQ ID NO: 29 45)
L-CDR3+1-opt.	-8-6-47	1.97 ± 0.29	0.62 ± 0.04	3.18 ± 0.33 ^c	QSYDYDHY (SEQ ID NO: 60)	SGSESNIGSNYVS (SEQ ID NO: 30 42)
L-CDR3+1-opt.	-8-10-57	1.65 ± 0.21	0.44 ± 0.06	2.67 ± 0.25 ^c	QSYDLIRH (SEQ ID NO: 4)	SGSESNIGNNYVQ (SEQ ID NO: 7)
L-CDR3+1-opt.	-8-27-7	1.74 ± 0.21	0.57 ± 0.07	3.30 ± 0.34 ^d	QSYDMNVH (SEQ ID NO: 5)	SGSESNIGNNYVG (SEQ ID NO: 17)
L-CDR3+1-opt.	-8-27-10	1.76 ± 0.21	0.53 ± 0.05	3.01 ± 0.21 ^c	QSYDMNVH (SEQ ID NO: 5)	SGSESNIGNNYVN (SEQ ID NO: 18)
L-CDR3+1-opt.	-8-27-41	1.67 ± 0.16	0.49 ± 0.03	2.93 ± 0.27 ^d	QSYDMNVH (SEQ ID NO: 5)	SGSESNIGNNYVQ (SEQ ID NO: 7)